Jet nebulisers are used to deliver a wide range of drugs as aerosols. The British National Formullarv lists not only six bronchodilator solutions in doses up to 10 mg (available in single dose ampoules, multidose vials, or both), but also one corticosteroid, one prophylactic agent (sodium cromoglycate), and two mucolytics as being suitable for nebulisation.' In addition, nebulisers have been used with varying degrees of success with other solutions, including water, saline, antihistamines, local anaesthetics, and antibiotics. They may also have a role to play in achieving high systemic concentrations of certain other drugs (for example, insulin2) that cannot be given orally. Nebulisers are operated by compressed gas (from a cylinder, hospital air or oxygen line or oil free compressor), and convert a drug solution into a respirable spray.
In hospital, nebulisers are used mainly to treat children and adults with asthma and bronchitis for example, using large doses of beta adrenergic bronchodilators. This means of treatment is associated with less tachycardia or tremor than oral or parenteral treatment. Others may be unable to use an inhaler because of incoordination (a particular problem in very young children), and others believe that the nebuliser will reduce the frequency of hospital admission. The increased use of home nebulisers has, however, been the subject of recent concern. The major worry is that many patients might place too much reliance on their nebulisers and delay seeking medical advice for instance, during a potentially fatal asthmatic attack. This problem hais been suggested though not proved as a cause of the recent increase in asthma deaths in New Zealand.7 A recent survey of a group of 53 users of home nebulisers, most of whom were less than 15 years of age, found that many were poorly supervised and instructed.' Eight of 49 patients with 'moderate' to ,severe' asthma were not attending a hospital clinic. only 20 ,ug to the lungs. As the bronchodilator threshold is fairly low the large nebuliser doses may be effective even if the nebuliser is incorrectly set up, but may often be unnecessarily high. There is now evidence, previously lacking, that efficient operation of nebulisers is important for delivery of bronchodilators; improved small airways bronchodilatation may be produced using nebulisers and flow rates that deliver aerosols of droplet size approximately 2 Am diameter. 12
Nebulisers can be used with virtually any drug solution or suspension, and sometimes it may be appropriate to deliver as much 'respirable' aerosol to the patient in the shortest possible treatment time. This may be the case for antibiotic aerosols, which have been used with moderate success to treat respiratory tract infection since the 1940s and which are now regarded as highly effective in the treatment of pseudomonas infection in some patients with cystic fibrosis. '3 Antibiotic solutions (particularly those made up from powders) are fairly viscous and hence are 'difficult' to nebulise.
In our laboratory at the Royal Free Hospital we have evaluated nebuliser systems in vitro to set out guidelines for delivery of aerosol antibiotics. Using gentamicin solution,'4 drug delivery was optimised by specific brands of nebuliser (DeVilbiss and Upmist) filled with 4 ml drug solution and operated at flows equivalent to those from the most powerful compressors available for domiciliary use. Overall, the output of 'respirable' (<5 Im diameter) gentamicin aerosol varied over a 10-fold range according to the type of nebuliser and its operating conditions. In a subsequent study using carbenicillin the conclusions were broadly similar, except that the Turret nebuliser was most efficient when used with 1 g carbenicillin powder plus 3 ml diluent (making a total volume 3.7 ml).'5 Again, drug output was optimised and nebulisation time made acceptably short by the use of powerful compressors.
Conclusion
It is difficult to recommend specific brands of nebuliser and compressor as the range of equipment available is changing continuously. Nevertheless, these results suggest that not all nebulisers and compressors are suitable for use with antibiotic solutions and that the use of inappropriate apparatus, inappropriately set up, may have been a cause of unsuccessful aerosol treatment in some previous clinical studies. Our data may also serve as a 'model' for the efficient delivery of various drug solutions not only for topical but also for systemic treatment.
We believe that rational nebuliser therapy can be a valuable addition in the management of several lung diseases. We would like to make a plea, however, for more consideration to be given to the specific indications for its use (namely, the delivery of fairly large doses of drugs, use by patients with poor metered dose inhaler technique, and the aerosolisation of drugs that cannot be delivered by other devices). We also stress the importance of satisfactory equipment properly set up in terms of flow rate and volume fill. Such supervision will dispel any fears of dangerous side effects and quell any 'nebuliser epidemic'.
